The purpose of this study is to learn more about what effects the use of high-dose-rate (HDR) brachytherapy on prostate cancer recurrence, seen by AXUMIN PET scan, has on prostate cancer.
In this study the investigator would like to better understand the use of high-dose rate (HDR) brachytherapy to target only recurrent prostate cancer that can be seen by AXUMIN PET scan. The use of HDR brachytherapy for prostate cancer is not new, but it is a more recent advancement to use it to treat only what can be seen instead of the whole prostate.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
High-Dose-Rate Brachytherapy Targeting only to AXUMIN PET Visible Lesion
University of Rochester
Rochester, New York, United States
Number of patients with prostate-specific antigen (PSA) levels rising of 2ng/ml or above
Rate of prostate-specific antigen (PSA) failure after focal salvage HDR in the setting of prostate only recurrence after primary non-surgical treatment, defined as a PSA rise of 2 ng/ml or more above the nadir at 6 months
Time frame: 6 Months
Incidence of Treatment-Related Adverse Events [Safety and Tolerability]
Measured by adverse event severity and quantity
Time frame: 6 Months
Progression Free Survival
Measure of time from study enrollment until progression.
Time frame: 6 Months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.